Minutes of the March 2, 2012
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division

Members present
Debra Farver, PharmD; Dana Darger, RPh; Timothy Soundy, MD; Bill Ladwig, RPh; James Engelbrecht, MD; Michelle Baack, MD; Mikel Holland, MD; Kelly Oehlke, PharmD; Lenny Petrick, PharmD

Members absent
Rick Holm, MD

DSS staff present
Mike Jockheck, RPh

HID staff present
Candace Rieth, PharmD

Administrative Business
The P&T meeting was called to order by D. Darger at approximately 1:00pm. The minutes of the December 9, 2011 meeting were presented. D. Farver made a motion to approve. K. Oehlke seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics
C. Rieth presented an overview of the prior authorization (PA) activity for October 2011. There were a total of 2,088 PAs processed in the month of January, with 98.04% of those requests responded to in less than 8 hours. There were 1,758 (84%) requests received electronically and 330 (16%) requests received by fax.

Analysis of the Top 15 Therapeutic Classes
C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 10/01/2011 – 12/31/2011. The top five classes were antipsychotics, cerebral stimulants, amphetamines, corticosteroids (respiratory tract), and leukotriene modifiers. The top 15 therapeutic classes make up 38.43% of total claims. C. Rieth also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 15.64% of total claims.

Review of PA forms
The committee reviewed all prior authorization forms and criteria. Suggested changes include:

1. Remove Cozaar from ARB form and remove other brand ARBS when their generic equivalent becomes available
2. Add Actemra, Stelara, Rituxan and add 'specialist involved in therapy' to TIM form
3. Add 'or intolerance to allopurinol' to Uloric algorithm
4. Remove Protonix from the PPI form
5. Add 'specialist involved in therapy' to Xolair form

Oral Anticoagulants Review
At the December meeting, the committee asked that a draft PA form for oral anticoagulants be brought to the March meeting. B. Ward, representing Boehringer Ingelheim, had a question for the committee. After review, a motion was made by J. Engelbrecht to amend the form to include the FDA approved indications for each drug as bullet points. D. Farver seconded the motion. The motion was approved unanimously. A motion was made by D. Farver to approve the amended form. T. Soundy seconded the motion. The motion was approved

unanimously. The committee requested that recipients currently taking these medications be grandfathered in the PA process.

ODT Review

C. Rieth presented information for orally disintegrating tablets currently available. There was no public comment. A motion was made by M. Baack to amend the form to include 'severe nausea or vomiting'. B. Ladwig seconded the motion. The motion was approved unanimously. A motion was made by J. Engelbrecht to approve the amended form. D. Farver seconded the motion. The motion was approved unanimously.

Antipsychotics used as Antidepressants Review

C. Rieth reviewed data for antipsychotics used as antidepressants. P. Arends, representing NAMI, had a question for the committee. D. Sproat, representing BMS, had a question for the committee. After review, the committee requested that data, including all of the antipsychotics that could be used in depression, be brought to the June meeting; that all prior recommendations related to antipsychotics be reviewed at the June meeting; and that Dr. Farver and Dr. Soundy draft a proposal for prior authorization of antipsychotics.

Low-dose Seroquel Review

Low-dose Seroquel will be reviewed with antipsychotics in June.

Lidoderm Review

C. Rieth reviewed Lidoderm clinical and utilization information. There was no public comment. The committee requested that diagnoses information for recipients receiving Lidoderm be brought to the June meeting.

Brilinta Review

C. Rieth reviewed Brilinta clinical and utilization information. There was no public comment. The committee requested that updated utilization information be provided at the June meeting.

Lorzone Review

C. Rieth reviewed Lorzone clinical and utilization information. There was no public comment. The committee requested that a Skeletal Muscle Relaxant class review be brought back to the June meeting.

The next meeting date is scheduled for June 22, 2012. The location will be the Sheraton Convention Center. A motion was made by M. Baack at 3:00pm to adjourn the SD Medicaid P&T meeting. K. Oehlke seconded the motion. Motion passed unanimously and the meeting was adjourned.